• Home
  • Sitemap
  • Help
  • Technical Support
  • Contact
Toolbar - View Selection
 
Items 1 of 1
ALX-350-105 Revised 05-Apr-08
Hellebrin
Add to Clipboard
SYNONYMS 3β-(O4-β-D-Glucopyranosyl-α-L-rhamnopyranosyloxy)-5,14-dihydroxy-19-oxo-5β,14-β-bufa-20,22-dienolide
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Natural Products - ATPase Inhibitors
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-105-M001   1 mg 45.00 USD Add To Cart
ALX-350-105-M005   5 mg 180.00 USD Add To Cart
Product Specification
FORMULA: C36H52O15
MW: 724.8
CAS NUMBER: 13289-18-4
SOURCE/HOST: Isolated from Helleborus sp.
PURITY: ≥99%
APPEARANCE: White solid.
SOLUBILITY: Soluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HAZARD: TOXIC.

Product Description
Cardiotonic glycoside which presents a bufadienolide-steroid structure. Besides ouabain (Prod. No. ALX-350-066), from the class of cardenolides hellebrin is the second unique water soluble cardiotonic glycoside. Extremely potent inhibitor of Na+/K+-ATPase  (sodium pump) blocking the active efflux of Na+ and reuptake of K+ of this membrane enzyme. Shows a positive inotropic effect by increasing the intracellular Ca2+ concentration. Strong immunosuppressor inhibiting T cell activity with much higher potency than cortisol or cyclosporin A (Prod. No. ALX-380-002). Induces caspase-dependent apoptosis.
Product Specific Literature References
Über Hellebrin, ein krystallisiertes Glykosid aus Radix Hellebori nigri: W. Karrer; Helv. Chim. Acta 26, 1353 (1943)
The structure of hellebrin: P. Muhr, et al.; Liebigs Ann. Org. Bioorg. Chem. 2, 443 (1995)
In search of ideal inotropic steroids: recent progress: K.R. Repke, et al.; Prog. Drug Res. 47, 9 (1996) Abstract
Exquisitely small amounts of nonglucocorticoid natural steroids suppress the human allogeneic T-cell response: P. Terness, et al.; Transplant Proc. 33, 547 (2001) Abstract
Apoptosis-mediated selective killing of malignant cells by cardiac steroids: maintenance of cytotoxicity and loss of cardiac activity of chemically modified derivatives: D. Daniel, et al.; Int. Immunopharmacol. 3, 1791 (2003) Abstract
 
 

Your items will be kept only for the duration of your visit.